The New Age Of Antihypertensives: Comparative Evaluation Of Benidipine And Azelnidipine In Blood Pressure Control
DOI:
https://doi.org/10.63682/jns.v14i32S.7656Keywords:
blood pressure, renoprotection, adverse effects, India, tertiary care hospital, calcium channel blockers, benidipine, azelnidipineAbstract
Objectives: To assess their impact on blood pressure control, cardiovascular risk factors, and adverse effect profiles in hypertension patients; also, to compare the efficacy and safety of Benidipine and Azelnidipine in the management of hypertension.
Methods: This observational, comparative study was carried out among Indian tertiary care hospital outpatient department attendees with hypertension. Assigned to either Benidipine or Azelnidipine as monotherapy or add-on treatment, eligible adult participants were Collected were baseline demographic, clinical, and laboratory data including blood pressure, serum uric acid, and lipid profile. To track blood pressure, evaluate effectiveness, and document side effects, patients were checked at set intervals. Blood pressure reduction, laboratory parameter improvement, and side effect incidence all determined effectiveness.
Results: Systolic and diastolic blood pressure was notably lowered by both benidipine and azelnidipine. Because of its triple calcium channel blocking action, benidipine exhibited extra renoprotective effects and a more sustained antihypertensive action. With extra advantages for insulin resistance and anti-atherosclerotic properties, azelnidipine was also efficient and well tolerated. In both groups, adverse effects were minor and rare; no major incident was recorded.
Benidipine and azelnidipine are safe and effective antihypertensive medications. While Azelnidipine provides good blood pressure reduction with favorable metabolic effects, Benidipine may offer extra renal protection and sustained blood pressure control. Patient comorbidities and tolerance help one to customize their choice of drugs.
Downloads
Metrics
References
Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis. 2011;18(1):28-41.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.
Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Hypertens Res. 2009;32(1):4-5.
Hirning LD, Fox AP, McCleskey EW, Olivera BM, Thayer SA, Miller RJ, et al. Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science. 1988;239(4836):57-61.
Sakata K, Shirotani M, Yoshida H, Kimura K, Kondo H, Sugiyama T, et al. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension. 1999;33(6):1447-52.
Hoshide S, Kario K, Ishikawa J, Eguchi K, Morinari M, Kaneda R, et al. Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure. Hypertens Res. 2005;28(12):1003-8.
Konno Y, Kimura K. Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int Heart J. 2008;49(6):723-32.
Fujita T, Ando K, Nishimura H, Ogawa S, Fujita M, Takagi J, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72(12):1543-9.
Nagasu H, Satoh M, Fujimoto S, Horike H, Komatsu Y, Tomita N, et al. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity. Hypertens Res. 2006;29(11):849-58.
Ohmura H, Matsuoka H, Yamaguchi T, Sakamoto T, Yoshida J, Miyamoto Y, et al. Azelnidipine reduces sympathetic nerve activity in patients with essential hypertension. Hypertens Res. 2006;29(6):363-9.
Ohmura H, Matsuoka H, Yamaguchi T, Sakamoto T, Yoshida J, Miyamoto Y, et al. Azelnidipine reduces proteinuria in patients with essential hypertension. Hypertens Res. 2007;30(6):557-63.
Kario K, Hoshide S, Uchiyama K, Nagasaka S, Shimada K, Imai Y. Effects of azelnidipine and amlodipine on ambulatory blood pressure and heart rate in hypertensive patients: the Azelnidipine and Amlodipine Randomized Double-blind Comparison (AZTEC) Study. Hypertens Res. 2009;32(1):45-50.
National Glycohemoglobin Standardization Program (NGSP). NGSP HbA1c methods. Available from: http://www.ngsp.org/.
Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107(10):1401-6.
Kario K, Eguchi K, Hoshide S, Hoshide Y, Umeda Y, Mitsuhashi T, et al. U-curve relationship between nighttime blood pressure and cardiovascular events in patients with hypertension. Hypertension. 2012;60(5):115-22.
Ohtomo S, Fujita T. N-type calcium channel in podocytes: a novel target for proteinuria. Kidney Int. 2007;72(10):1213-4.
Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83(1):253-307.
Ohtsuka Y, Yamakawa T, Kato K, Iwata S, Sugino N, Suzuki K, et al. Increased hypoxanthine production by skeletal muscle during exercise in patients with hypertension. Hypertension. 1994;23(6 Pt 2):803-8.
Ohtsuka Y, Yamakawa T, Kato K, Iwata S, Sugino N, Suzuki K, et al. Cilnidipine decreases hypoxanthine production by skeletal muscle during exercise in patients with hypertension. J Cardiovasc Pharmacol. 2002;39(6):816-21.
Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Ito S, Shimamoto K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. Hypertens Res. 2011;34(9):1006-1015.
Saito I, Kushiro T, Saito Y, Ogawa H, Okada Y, Kuramoto K, et al. Effect of anti-hypertensive treatment on cardiovascular events in elderly hypertensive patients: Japan’s Benidipine Research on Anti-Hypertensive Effects in the Elderly (J-BRAVE). Hypertens Res. 2011;34(9):1048-1053.
Qi W, Wang J, Wang Y, Zhang Y, Li Y, Wang Y, et al. Anti-hypertensive efficacy and safety of benidipine and its effects on cardiac structure and function in elderly Chinese patients with mild to moderate hypertension: an open-label, long-term study. Clin Exp Hypertens. 2011;33(5):299-306.
Yao K, Shirai K, Sasaki H, Kuno T, Kimura S, Shibata S. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J Pharmacol Sci. 2006;100(3):243-261.
Kita T, Kitamura K, Fujii K, Ohnishi H, Sasaki J, Kario K, et al. Long-term anti-hypertensive therapy with benidipine improves arterial stiffness over blood pressure lowering. Hypertens Res. 2005;28(7):573-579.
Chen BL, Li Y, Wang Y, Zhang Y, Wang Y, Wang J, et al. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Drug Des Devel Ther. 2015;9:605-612.
Kario K, Hoshide S, Uchiyama K, Nagasaka S, Shimada K, Imai Y. Inhibitory effects of azelnidipine tablets on morning hypertension. Hypertens Res. 2013;36(7):616-622.
Watanabe M, Koyama S, Nakashima H, Koyama S, Takashima S, Koyama S, et al. Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients: a 123I-IMP SPECT follow-up study. Hypertens Res. 2010;33(7):675-680.
Yamagishi T. Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. Hypertens Res. 2006;29(7):567-573.
Arita M, Ito S, Sato Y, Kinoshita M, Kato M, Yamaguchi I. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. Hypertens Res. 2003;26(5):377-384.
Yao K, Nagashima K, Miki H. Pharmacological, Pharmacokinetic, and Clinical Properties of Benidipine Hydrochloride, a Novel, Long-Acting Calcium Channel Blocker. J Pharmacol Sci. 2006;100(4):243-261. doi:10.1254/jphs. DTJ05001X
Yamagishi T. Efficacy of Azelnidipine on Home Blood Pressure and Pulse Rate in Patients with Essential Hypertension: Comparison with Amlodipine. Hypertens Res. 2006;29(10):767-773. doi:10.1291/hypres.29.767
Kario K, Sato Y, Shirayama M, et al. Inhibitory Effects of Azelnidipine Tablets on Morning Hypertension. Drugs RD. 2013;13(1):63-73. doi:10.1007/s40268-013-0006-8
Matsuzaki M, Ogihara T, Umemoto S, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29(8):1649-1659. doi:10.1097/HJH.0b013e328348345d
Zhang W, Chen B, Zhang Y, Luo J. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Ther Clin Risk Manag. Published online February 2015:309. doi:10.2147/TCRM.S64288
Arita M, Hashizume T, Tanigawa K, Yamamoto H, Nishio I. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol. 1999;33(2):186-192. doi:10.1097/00005344-199902000-00003
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
